{"filing":{"accession_number":"0001193125-26-377362","cik":"0001628171","ticker":"RVMDW","company_name":"Revolution Medicines, Inc.","form":"8-K","filing_date":"2026-09-01","report_date":"2026-08-27","primary_document":"rvmd-20260827.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526377362/rvmd-20260827.htm"},"events":[{"id":30727,"run_id":28172,"accession_number":"0001193125-26-377362","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Revolution Medicines entered into four material lease agreements on August 27, 2026 for approximately 672,000 square feet of space in Redwood City, California to serve as its new headquarters, involving substantial financial commitments including approximately $2.7 million in monthly base rent at full commencement, $23.1 million in rent abatement, and $115.9 million in tenant improvement allowances.","company_name":"Revolution Medicines, Inc.","ticker":"RVMDW","filing_date":"2026-09-01","form":"8-K","submitted_at":null,"items":[{"id":33426,"accession_number":"0001193125-26-377362","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Revolution Medicines entered into four material lease agreements on August 27, 2026 for approximately 672,000 square feet of space in Redwood City, California to serve as its new headquarters. The transaction involves substantial financial commitments—approximately $2.7 million in monthly base rent at full commencement, $23.1 million in rent abatement, and $115.9 million in tenant improvement allowances—making it a material operational and strategic commitment. While this is a real estate transaction rather than a traditional M\u0026A activity, it represents a significant capital deployment and operational decision that would affect a reasonable investor's assessment of the company's strategic direction and financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T10:08:58.409435+00:00","company_name":"","ticker":null,"filing_date":""},{"id":33427,"accession_number":"0001193125-26-377362","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.45,"reasoning":"Item 2.03 is filed and references incorporation of Item 1.01 details, which typically covers material acquisitions or direct financial obligations. The disclosure mentions \"Phase II Closing\" and lease arrangements with anticipated costs, suggesting a material financial commitment. However, the provided text is incomplete—it lacks the substantive details from Item 1.01 that would clarify whether this is a debt issuance, lease obligation, or other financial arrangement. The forward-looking statements reference \"relocation and occupancy costs\" and \"Phase II Closing,\" indicating a significant capital commitment, but without the full Item 1.01 disclosure, the precise nature and materiality cannot be definitively determined.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T10:08:58.409435+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33426,"accession_number":"0001193125-26-377362","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Revolution Medicines entered into four material lease agreements on August 27, 2026 for approximately 672,000 square feet of space in Redwood City, California to serve as its new headquarters. The transaction involves substantial financial commitments—approximately $2.7 million in monthly base rent at full commencement, $23.1 million in rent abatement, and $115.9 million in tenant improvement allowances—making it a material operational and strategic commitment. While this is a real estate transaction rather than a traditional M\u0026A activity, it represents a significant capital deployment and operational decision that would affect a reasonable investor's assessment of the company's strategic direction and financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T10:08:58.409435+00:00","company_name":"Revolution Medicines, Inc.","ticker":"RVMDW","filing_date":"2026-09-01"},{"id":33427,"accession_number":"0001193125-26-377362","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.45,"reasoning":"Item 2.03 is filed and references incorporation of Item 1.01 details, which typically covers material acquisitions or direct financial obligations. The disclosure mentions \"Phase II Closing\" and lease arrangements with anticipated costs, suggesting a material financial commitment. However, the provided text is incomplete—it lacks the substantive details from Item 1.01 that would clarify whether this is a debt issuance, lease obligation, or other financial arrangement. The forward-looking statements reference \"relocation and occupancy costs\" and \"Phase II Closing,\" indicating a significant capital commitment, but without the full Item 1.01 disclosure, the precise nature and materiality cannot be definitively determined.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T10:08:58.409435+00:00","company_name":"Revolution Medicines, Inc.","ticker":"RVMDW","filing_date":"2026-09-01"}]}